Principle Investigator – Duxin Sun

PharmHdsSep22(02)-rev.jpg

Dr. Duxin Sun is the Associate Dean for Research in the College of Pharmacy at the University of Michigan. He is the Charles Walgreen Jr. Professor of Pharmacy and Professor of Pharmaceutical Sciences, and serves as the Director of the Pharmacokinetics (PK) Core. Dr. Sun also has a joint appointment in the Chemical Biology program, the Interdisciplinary Medicinal Chemistry program, and University of Michigan's Comprehensive Cancer Center.

Dr. Sun’s research interests focus on drug development, nanomedicine, and pharmacokinetics. Dr. Sun developed the STAR system (Structure-Tissue/Cell Selectivity-Activity-Relationship) to enhance drug development success by addressing the 90% failure rate. He also proposed a drug/nanocarrier-specific anticancer nanomedicine design strategy to enhance thier clinical efficacy and improve clinical success.  Dr. Sun earned his BS in Pharmacy, MS in Pharmacology, and PhD in Pharmaceutical Sciences, and has also received training in Molecular Biology as a visiting scientist. With research experience in both academia and the pharmaceutical industry, Dr. Sun has published over 260 papers, and has mentored 37 PhD students and 70 postdoctoral fellows/visiting scientists.

Dr. Sun is an elected Fellow of both the American Association for the Advancement of Science (AAAS) and the American Association of Pharmaceutical Scientists (AAPS). He has served on the FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee and participated in study sections for the NIH and FDA.

Research Introduction to General Public: Drug Development and NanoMedicine

1. 90% of drugs fail clinical trials – here’s one way researchers can select better drug candidates. Conversation, Feburary 23, 2022

2. Nanoparticles are the future of medicine – researchers are experimenting with new ways to design tiny particle treatments for cancer. Conversation, May 4, 2022

Research Introduction to Scientists: Drug Development, NanoMedicine, Pharmacokinetics

1. Why most anticancer nanomedicines do not enhance clinical efficacy and how to improve it ?

2. Why 90% of drug development fails and how to improve it? (PPT Slides, Video Recording)

3. Why most cancer vaccines only achieve short-term efficacy and how to improve it?

4. What are the differences of microbiome, bile salts, and drug release in different regions of human GI tract?

Drug Development, NanoMedicine, Pharmacokinetics-6-6-2023.jpg